TERN - NASDAQ
Terns Pharmaceuticals, Inc.
$52.95
+0.0000%Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
At a Glance
Live Snapshottern
Sales/Maturities of Investments
Last Annual Value
107.00M
3-Year CAGR
-3%
5-Year CAGR
68%
10-Year CAGR
46%
Terns Pharmaceuticals, Inc. Competitors Analysis of Sales/Maturities of Investments
| Company | Sales/Maturities of Investments | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Terns Pharmaceuticals, Inc. NASDAQ:TERN | 107.00M | -23.4% | 17.9% | N/A | |
 Relay Therapeutics, Inc. NASDAQ:RLAY | 316.18M | -21.2% | -9.8% | N/A | |
 Nektar Therapeutics NASDAQ:NKTR | 284.68M | -24.1% | -24.7% | 1.0% | |
 Inhibrx Biosciences, Inc. NASDAQ:INBX | 0.00 | N/A | N/A | N/A | |
 Amylyx Pharmaceuticals, Inc. NASDAQ:AMLX | 246.00M | -14.5% | 141.4% | N/A | |
 ORIC Pharmaceuticals, Inc. NASDAQ:ORIC | 252.50M | 8.7% | 2.0% | N/A | |
 Syndax Pharmaceuticals, Inc. NASDAQ:SNDX | 486.03M | 1.0% | 13.9% | 13.2% | |
 Tourmaline Bio, Inc. NASDAQ:TRML | 171.84M | 103.1% | -1.1% | N/A | |
 Enliven Therapeutics, Inc. NASDAQ:ELVN | 272.90M | 31.5% | 42.8% | N/A | |
 Precigen, Inc. NASDAQ:PGEN | 208.47M | 4.4% | 15.8% | 7.4% |
Terns Pharmaceuticals, Inc. Fair Value Envelope
Related Guides
Continue your TERN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.